Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial

杜瓦卢马布 医学 膀胱切除术 膀胱癌 银耳霉素 放射治疗 内科学 泌尿科 肿瘤科 泌尿生殖系统 临床终点 外科 免疫疗法 癌症 临床试验 易普利姆玛 无容量
作者
Xavier García del Muro,Begoña P. Valderrama,Ana Medina,Olatz Etxániz,Regina Gironés Sarrió,María José Juan-Fita,Marcel Costa-García,Rafael Moreno,Isabel Miras Rodríguez,Irene Ortiz,Andrés Cuéllar,Ferran Ferrer,Francesc Vigués,Roberto de Haro Piedra,Arturo Candal Gómez,S. Villà,José Luís Pontones,Yasmina Murria,Guillermo Lendínez‐Cano,Ramón Alemany
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:31 (4): 659-666 被引量:23
标识
DOI:10.1158/1078-0432.ccr-24-2636
摘要

PURPOSE: The combination of radiation and immunotherapy potentiated antitumor activity in preclinical models. The purpose of this study is to explore the feasibility, safety, and efficacy of a bladder-preserving approach, including dual immune checkpoint blockade and radiotherapy, in patients with muscle-invasive bladder cancer (MIBC). PATIENTS AND METHODS: Patients with localized MIBC underwent transurethral resection, followed by durvalumab (1,500 mg) plus tremelimumab (75 mg) every 4 weeks for three doses and concurrent radiotherapy (64-66 Gy to bladder). Patients with residual or relapsed MIBC underwent salvage cystectomy. The primary endpoint was complete response, defined as the absence of MIBC at posttreatment biopsy. Secondary endpoints were bladder-intact disease-free survival, distant metastasis-free survival, and overall survival. RESULTS: Thirty-two patients were enrolled at six centers. Complete response was documented in 26 (81%) patients. Two patients had residual MIBC, and four patients were not evaluated. After a median follow-up of 27 months, 2 patients underwent salvage cystectomy. The 2-year rates for bladder-intact disease-free survival, distant metastasis-free survival, and overall survival were 65%, 83%, and 84%, respectively. The 2-year estimates of non-muscle-invasive bladder relapse, MIBC, and distant metastasis were 3%, 19%, and 16%, respectively. Grade 3 to 4 toxicities were reported in 31% of patients, with diarrhea (6%) and acute kidney failure (6%) being the most frequent. CONCLUSIONS: This multimodal approach including durvalumab plus tremelimumab with concurrent radiotherapy is feasible and safe, showing high efficacy in terms of response and eliciting bladder preservation in a large number of patients. Further research on this approach as an alternative to cystectomy is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
孤独的狼完成签到,获得积分10
1秒前
彩色青亦发布了新的文献求助10
1秒前
qqqqqqqqqq发布了新的文献求助10
2秒前
3秒前
子为春树完成签到,获得积分10
3秒前
英俊的铭的应助被小猛人采纳,获得10
4秒前
英姑的应助被旺旺雪饼采纳,获得10
4秒前
LANER发布了新的文献求助10
4秒前
5秒前
qaz123发布了新的文献求助10
5秒前
Wqhao完成签到,获得积分10
5秒前
6秒前
秦博完成签到,获得积分10
6秒前
6秒前
风趣的莞发布了新的文献求助10
6秒前
zpz2678完成签到,获得积分10
6秒前
哈哈哈发布了新的文献求助10
6秒前
叮咚完成签到,获得积分20
7秒前
7秒前
TAOS完成签到,获得积分10
8秒前
FashionBoy的应助被Panda采纳,获得10
8秒前
succo完成签到,获得积分20
8秒前
9秒前
JamesPei的应助被kk采纳,获得10
9秒前
10秒前
10秒前
10秒前
relevance完成签到,获得积分10
11秒前
狮子座发布了新的文献求助10
11秒前
11秒前
12秒前
姜姗发布了新的文献求助10
12秒前
ruan发布了新的文献求助10
13秒前
13秒前
13秒前
Orange发布了新的文献求助10
16秒前
英勇青烟完成签到,获得积分10
16秒前
17秒前
kukudixiaole发布了新的文献求助10
17秒前
脑洞疼的应助被horse82采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194107
求助须知:如何正确求助?哪些是违规求助? 9580062
关于积分的说明 21869017
捐赠科研通 7793713
什么是DOI,文献DOI怎么找? 3437523
关于科研通互助平台的介绍 2560962
邀请新用户注册赠送积分活动 2484264